{"id":"W2970412630","doi":"10.1053/j.ajkd.2019.06.009","title":"Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency","year":2019,"lang":"en","type":"article","venue":"American Journal of Kidney Diseases","topic":"Chronic Kidney Disease and Diabetes","field":"Medicine","cited_by":561,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia","funders":"Relypsa; Sanofi Genzyme; National Institutes of Health; Siemens; Novo Nordisk; Servier; Kyowa Hakko Kirin; Ipsen; Astellas Pharma Canada; Ironwood Pharmaceuticals, Incorporated; Alexion Pharmaceuticals; Boehringer Ingelheim; Gilead Sciences; Novartis; AbbVie; Merck; Tufts Medical Center; Bayer; AstraZeneca","keywords":"Medicine; Renal function; Kidney disease; Albuminuria; Clinical trial; Observational study; Hazard ratio; Creatinine; Internal medicine; Intensive care medicine; Surrogate endpoint; Urology; Confidence interval","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004199613,0.0001325818,0.0005243665,0.0002376059,0.00005189098,0.00008576668,0.00008015573,0.00002407058,0.00002320463],"category_scores_gemma":[0.01280275,0.00007724779,0.00005690608,0.0004558046,0.0006128393,0.0003034586,0.00002116782,0.000129892,4.093658e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004443455,"about_ca_system_score_gemma":0.001592254,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000380316,"about_ca_topic_score_gemma":0.00007615887,"domain_scores_codex":[0.9974607,0.0009861118,0.0007939514,0.0002253232,0.0003882207,0.0001456952],"domain_scores_gemma":[0.9966511,0.001721849,0.0007988701,0.0001150174,0.0002442973,0.0004688821],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004863111,0.0004714867,0.9690222,0.0001821253,0.0001163952,0.00001076098,0.003299524,8.657997e-7,0.0009610605,0.00007187481,0.007025474,0.01397513],"study_design_scores_gemma":[0.009486972,0.002592423,0.9809157,0.001077868,0.0002888225,0.00001916973,0.003368876,0.0001122962,0.0001887605,0.000225541,0.001593029,0.0001305554],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9757132,0.001420326,0.000003597545,0.02161446,0.00008215738,0.0009341056,0.0002049032,0.000002849017,0.00002442459],"genre_scores_gemma":[0.9969815,0.0004116837,0.00005888426,0.002248,0.0001412957,0.00002665564,0.00008567648,0.00001315625,0.00003316696],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02126831,"threshold_uncertainty_score":0.9955128,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04026963815954018,"score_gpt":0.3754556381424535,"score_spread":0.3351859999829133,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}